Safety and Efficacy of a Vascular Prosthesis for Hemodialysis Access in Patients With End-Stage Renal Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01840956|
Recruitment Status : Completed
First Posted : April 26, 2013
Last Update Posted : August 19, 2022
The purpose of this study is to assess the safety and efficacy of a novel, tissue-engineered vascular prosthesis, the Human Acellular Vascular Graft, HAVG.
The HAVG is intended as an alternative to synthetic materials and to autologous grafts in the creation of vascular access for dialysis.
|Condition or disease||Intervention/treatment||Phase|
|End-stage Renal Disease Kidney Failure, Chronic||Biological: HAVG||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase I Study for the Evaluation of Safety and Efficacy of Humacyte's Human Acellular Vascular Graft for Use as a Vascular Prosthesis for Hemodialysis Access in Patients With End-Stage Renal Disease|
|Actual Study Start Date :||May 23, 2013|
|Actual Primary Completion Date :||April 28, 2016|
|Actual Study Completion Date :||April 28, 2016|
Surgical placement of HAVG
HAVG is implanted into patients' arm.
- HAVG graft assessment [ Time Frame: From baseline to week 26 after HAVG implantation. ]The incidence of aneurysm formation, anastomotic bleeding or rupture, graft infection and irritation/inflammation/infection at the implantation site will be assessed by Doppler ultrasound and tabulated.
- HAVG patency rate [ Time Frame: at Week 26 after HAVG implantation ]Determine the patency (primary, primary assisted and secondary) rate of the Humacyte HAVG by Doppler ultrasound.
- Adverse Events [ Time Frame: From baseline to week 26 after HAVG implantation. ]Frequency and severity of AEs of each patient will be documented.
- HAVG graft interventions [ Time Frame: From baseline to week 26 after HAVG implantation. ]Graft interventions of each patient will be documented.
- Change from baseline in Panel Reactive Antibody [ Time Frame: From baseline to day 29, weeks 12 and 26 after HAVG implantation. ]Assess changes in the Panel Reactive Antibody response over the 6 months after graft implantation.
- Development of IgG antibodies [ Time Frame: From baseline to day 29, weeks 12 and 26 after HAVG implantation. ]Determine whether IgG antibodies to the extracellular matrix material are formed in response to implantation of the HAVG.
- Graft interventions [ Time Frame: At each visit, i.e. day 1, day 4-7, day 15, day 29, day 57, week 12, week 16, 20, 26 after HAVG implantation. ]Determine the rates of interventions needed to maintain / restore patency in the graft.
- HAVG patency rates [ Time Frame: at 12, 18, 24 months after HAVG implantation. ]Patency rates (primary, primary assisted, and secondary)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01840956
|United States, North Carolina|
|Duke University Medical Center Department of Vascular Surgery|
|Durham, North Carolina, United States, 27710|
|United States, Texas|
|The Methodist Hospital|
|Houston, Texas, United States, 77030|
|United States, Virginia|
|Sentara Norfolk General Hospital Vascular & Transplant Specialists|
|Norfolk, Virginia, United States, 23507|
|Study Director:||Lynda H Szczech, MD, MSCE||Humacyte, Inc.|